Azacitidine Compared to Conventional Chemotherapy in Consolidation of Elderly Patients (65 Years or Older) With AML in First Complete Remission

Trial Profile

Azacitidine Compared to Conventional Chemotherapy in Consolidation of Elderly Patients (65 Years or Older) With AML in First Complete Remission

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2015

At a glance

  • Drugs Azacitidine (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2015 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top